



Press Release

Montpellier, France, April 20, 2022 – 6:00 pm CEST

Availability of the 2021 annual financial report

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, announces today the publication of its Annual Financial Report for the year ended December 31, 2021. This Annual Financial Report was approved by the Board of Directors on April 19, 2022.

"2021 has been a rich year for Intrasense, with the initiation of a new phase of development for the Group and an ever-stronger ambition for growth and value creation."

Nicolas Reymond, CEO of Intrasense

Financial indicators in Strong growth

The financial report for the year 2021 confirms the turnaround taken by the Intrasense Group, which is accelerating its growth momentum, with record revenues and a positive evolution of its gross margin.

Fueled by a capital increase, successfully completed in June 2021, and supported by an ambitious growth plan, the Group's commercial dynamism is strengthening on its key markets, Europe and China.

These good results confirm the strategic relevance of the Group's investments. They also demonstrate the success of Intrasense's industrial and commercial expansion policy, based on innovation and the strengthening of its sales teams. The outlook is promising in the fast-growing radiology and oncology markets, notably thanks to new partnerships and the development of the new Myra product line.

Key financial indicators:

- Revenues up by +22% compared to 2020
- Gross profit was up by +21%
- Cash position strengthened to nearly €4.8 million
- Continued strategic investments to accelerate growth in 2022



The annual financial report can be consulted and downloaded, as of today, in the "Investors" section of the company's website:

<https://www.intrasense.fr/investors/#financial-documentation>.

It includes the following information:

- The management report of the Board of Directors on the activity of the company and the Group during the financial year ending December 31, 2021
- The report on corporate governance
- The notes to the consolidated and individual financial statements
- The various reports of the Statutory Auditors

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has 56 employees among which 16 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense

Anne-Elisabeth Achiri
Communications Officer
Tel: +33 4 67 13 01 30
investor@intrasense.fr

NewCap

Olivier Bricaud
Investor Relations and
Financial Communication
Tel: +33 1 44 71 00 14
intrasense@newcap.eu

